TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00993486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Description: Single intravenous infusion
Study: NCT02125162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161
Description: Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161
Description: Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161
Description: Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
Study: NCT02337023

Intervention type: RADIATION
Intervention: Brain scintigraphy with injection of Neurolite® (ECD)
Description: Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
Study: NCT03681405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive caring attention phone call
Study: NCT00804544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: SPECT/Low-Dose MultiSclice CT
Study: NCT01410201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Intravitreal Implant
Description: Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intravitreal Implant
Description: Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
Study: NCT04146324

Intervention type: DRUG
Intervention: nivolumab
Description: Administered as adjuvant therapy as per the market authorization in Australia
Study: NCT01756898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ASB17061
Description: Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo taken once daily for 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ASB17061
Description: Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ASB17061
Description: Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
Study: NCT03727347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSeca Stylus
Description: Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
Study: NCT04238702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 MG 7 days intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 MG 7 days intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50Mg Tab
Description: Losartan 50 MG 7 days intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50Mg Tab
Description: Losartan 50 MG 7 days intervention period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 7 days intervention period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 7 days intervention period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 7 days intervention period
Study: NCT01233531

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: monthly cash transfer payments for attending school
Description: In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: monthly cash transfer payments for attending school
Description: In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: B--No cash transfers
Description: No monthly cash transfers
Study: NCT02275468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu-zheng-qu-zhuo (FZQZ) oral liquid
Description: FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
Study: NCT01737697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium silicate (acute phase)
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium silicate (subacute phase)
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (acute phase)
Description: Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( subacute phase)
Description: Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
Study: NCT00596375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lubricant Instillation
Description: Lubricant jelly instilled in urethra prior to catheterization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Lubricant
Description: 2% Lidocaine lubricant instillation prior to urethral catheterization
Study: NCT03249883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SACH prosthetic foot, 1M10 prosthetic foot
Description: In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks.
Study: NCT01401985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules
Study: NCT01666353

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)
Description: PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
Study: NCT04281108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo orally disintegrating tablet.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
Study: NCT02812329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV prevention videogame
Description: Assess acceptability and efficacy of a HIV prevention videogame
Study: NCT01858506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I-ACE intervention
Description: lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Advice
Description: lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
Study: NCT01950741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
Study: NCT01435200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Description: Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous iron
Description: Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Study: NCT05127668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airglove (TM)
Description: A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm-water Immersion
Description: The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
Study: NCT04336085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caudal block
Description: Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
Study: NCT03121638

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX
Description: Preparation of Oka/Merck strain of live, attenuated varicella zoster virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX
Description: Preparation of Oka/Merck strain of live, attenuated varicella zoster virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP6081
Description: Preparation of Oka/SK strain of live, attenuated varicella zoster virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP6082
Description: Preparation of Oka/SK strain of live, attenuated varicella zoster virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP6083
Description: Preparation of Oka/SK strain of live, attenuated varicella zoster virus
Study: NCT03191994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: a structured, supervised eight week moderate intensity exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: a structured, supervised eight week moderate intensity exercise intervention
Study: NCT04859361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara 5% Topical Cream
Description: 5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ
Description: LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
Study: NCT00268593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
Study: NCT00086827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study: NCT00268593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg twice a day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg twice a day orally
Study: NCT00086827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04945005

Intervention type: PROCEDURE
Intervention: Transesophageal guidance of lead implantation
Description: In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
Study: NCT03237949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone counseling
Description: Four telephone counseling sessions using a motivational interviewing approach
Study: NCT03930797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement
Description: The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Healthy Together
Description: The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
Study: NCT03200860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: 10 mg daily, oral, 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching Placebo, 10 mg daily, oral, 30 days
Study: NCT01322139

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray and oral moxifloxacin placebo
Description: 24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex spray and oral moxifloxacin placebo
Description: 8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex spray and oral moxifloxacin placebo
Description: 24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo spray and moxifloxacin
Description: 24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
Study: NCT02261155

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hypnosis
Description: hypnotic Relaxation without specific analgesic suggestion
Study: NCT02590614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU Vitamin D
Description: Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
Study: NCT03237949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
Study: NCT02590614

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
Study: NCT02872194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516, Y55-170
Description: 10 uL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516, X72-151
Description: 10 uL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516, Y49-034
Description: 10 uL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (control)
Description: 10 uL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (control)
Description: 10 uL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (control)
Description: 10 uL in one eye
Study: NCT01858298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment: pulpectomy and composite resin crown

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-conservative treatment: Tooth extraction
Study: NCT00033449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00357786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Replagal agalsidase alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Replagal
Study: NCT00995189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Free RepleniSH
Description: Contact lens care solution containing polyquaternium-1 (PQT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus
Description: Contact lens care solution containing polyhexamethylene biguanide (PHMB)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses
Description: Daily wear, frequent replacement contact lenses per participant's habitual brand and power.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Daily wear, frequent replacement contact lenses per participant's habitual brand and power.